US LNG exports surge but will buyers in China turn up?
Investing.com - RBC Capital has raised its price target on PTC Therapeutics (NASDAQ:PTCT) to $63.00 from $60.00 while maintaining an Outperform rating on Friday. The $3.7 billion market cap company, currently trading at $47.15, has demonstrated remarkable growth with revenue surging 91% over the last twelve months. According to InvestingPro analysis, the stock appears undervalued at current levels.
The firm cited the resilience of PTC (NASDAQ:PTC)’s Translarna drug, which it believes will help bridge the company into what is expected to be a strong launch of Sephience.
RBC Capital noted that the Sephience launch is likely to remain the primary focus for investors, helping to offset what appears to be a probable regulatory delay or rejection for vatiquinone in FA later this month.
The firm sees potential upside to financial projections based on potentially strong commercial performance for Sephience, which could drive the stock higher toward what RBC now considers a $63 fair value.
RBC Capital stated it remains buyers of PTC Therapeutics shares ahead of the PKU (phenylketonuria) treatment launch.
In other recent news, PTC Therapeutics reported its financial results for the second quarter of 2025, exceeding analyst expectations. The company posted an earnings per share (EPS) of -0.83, beating the forecasted -1.06. Revenue also surpassed projections, reaching $179 million compared to the anticipated $171.74 million. These results highlight the company’s financial performance in the recent quarter. Additionally, TD Cowen raised its price target for PTC Therapeutics from $52 to $56 while maintaining a Hold rating. This decision was influenced by the successful launch of Sephience in both the U.S. and European markets. TD Cowen noted that the trajectory of Sephience will likely influence stock performance as the importance of the company’s Duchenne muscular dystrophy franchise diminishes. These developments provide insight into the company’s current market position and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.